P. R. Fleck
Publications While At Healthpartners
Cardiovascular mortality in patients with type 2 diabetes and recent acute coronary syndromes from the EXAMINE Trial
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
New England Journal of Medicine.
EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome
American Heart Journal.
Mortality findings from the EXAMINE Trial [abstract]
Major cardiovascular outcomes in the EXAMINE trial according to ACE inhibitor use [abstract]
Map of science